Clinical Forum

Pharmacologic approaches can increase the use of injectables.

New strategies can improve cholesterol management in patients with ASCVD.

When treating patients with graft-vs-host disease, pharmacists are often responsible for selecting treatment regimens while navigating other spheres of care.

Certain patients may present asymptomatically, affecting treatment options.

The pharmacist’s role may vary across different practices and institutions.

The complexity of the disease and number of treatment options can necessitate a personalized approach.

This frequency can allow for faster observation of toxicities and adherence issues.

In addition to the current principles and treatment regimens, there are upcoming data on myelofibrosis drugs that could be reported as early as 2024.

Treatment options can be limited for this patient population.

Although treatment is effective, AEs remain difficult for patients.

The fast pace of information can make it difficult to efficiently apply data to care.

Pharmacists can improve both quality of life and financial toxicity for patients.

Pharmacists also have the resources to help advocate for better care for patients.

A plethora of targeted therapies, biomarker-driven therapies, and immunotherapies are now available.

High-risk areas for disease progression include genitalia and the scalp.

An expert shares information on risk factors and controversies around testing.

Pharmacologic approaches can reduce the risk of chronic GVHD.